Breaking News Instant updates and real-time market news.

HON

Honeywell

$105.77

-9.84 (-8.51%)

, GPS

Gap

$26.04

3.255 (14.29%)

12:27
10/07/16
10/07
12:27
10/07/16
12:27

On The Fly: Top stock stories at midday

Stocks began the session in positive territory but were unable to hold their opening gains. The generally tame jobs data appeared to not move the needle on whether the Fed would be pushed to increase interest rates at its September meeting. The averages crossed into negative territory and remained within striking distance of the flat line until a report said the Atlanta Fed had cut its GDP forecast. The growth rate prediction was dropped to 2.1% from 2.2%, bringing with it more downside momentum. ECONOMIC NEWS: In the U.S., nonfarm payrolls increased 156,000 in September following August's upwardly revised 167,000 gain, but was still weaker than the 172,000 median forecast of economists. The unemployment rate rose to 5% from 4.9% previously. The wholesale report slightly underperformed with 0.2% August inventory drop. In Europe, German industrial production rose 2.5% in August, while U.K. industrial production fell by 0.4% due to a drop in oil and gas production. Additionally, the British pound plunged more than 6% in early morning trading, sending the currency to a new 31-year low. The "flash crash" has traders baffled, as some have pointed to a potential trader error and others have blamed the price action on Brexit fears and remarks from French President Francois Hollande calling for tough Brexit talks. COMPANY NEWS: Shares of Honeywell (HON) have dropped over 8% after the company reported preliminary third-quarter profit below its prior forecast and cut the top end of the 2016 earnings target as sales slump for aircraft parts... Meanwhile, shares of Gap (GPS) have advanced about 14% after the retailer said same-store sales increased 4% at its Old Navy brand in September, despite its namesake brand again posting lower comparable sales. MAJOR MOVERS: Among the notable gainers was Ralph Lauren (RL), which advanced 2% after the apparel maker was added to the Conviction Buy list at Goldman Sachs, with the firm citing the implementation of the company's turnaround plan. Also higher was Allegiant Travel (ALGT), which gained almost 2% after Imperial Capital analyst Michael Derchin started the stock with an Outperform rating, saying the company's "differentiated, low cost business model with strong growth prospects" is not fully reflected in current equity values. Among the noteworthy losers was Clovis Oncology (CLVS), which slipped 16% after the company announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib, which is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in select patients. Adam Feuerstein, biotech reporter for TheStreet.com, commented that the weakness in Clovis shares is likely due to comparisons being made between its data and AstraZeneca's (AZN) Lynparza, another drug in the same space that is already approved to treat certain ovarian cancer patients. Also lower was PPG Industries (PPG), which slid over 9% after the company cut its 2016 fiscal third quarter guidance. Additionally, Tyson Foods (TSN) dropped about 10% after research firm Pivotal Research downgraded the stock two notches to Sell from Buy, saying that a new class action lawsuit will lead to "intense scrutiny" of chicken producers, will cause investors to question the sustainability of chicken margins, and will probably cause Tyson's multiple to decline. INDEXES: Near midday, the Dow was down 93.34, or 0.51%, to 18,175.16, the Nasdaq was down 34.51, or 0.65%, to 5,272.35, and the S&P 500 was down 13.56, or 0.63%, to 2,147.21.

HON

Honeywell

$105.77

-9.84 (-8.51%)

GPS

Gap

$26.04

3.255 (14.29%)

RL

Ralph Lauren

$103.21

1.8 (1.78%)

ALGT

Allegiant Travel

$142.36

2.73 (1.96%)

CLVS

Clovis

$35.77

-1.51 (-4.05%)

AZN

AstraZeneca

$32.05

-0.21 (-0.65%)

PPG

PPG

$93.17

-9.02 (-8.83%)

TSN

Tyson Foods

$66.58

-7.8 (-10.49%)

  • 07

    Oct

  • 12

    Oct

  • 20

    Oct

  • 21

    Oct

  • 26

    Oct

  • 06

    Nov

  • 16

    Nov

  • 23

    Feb

HON Honeywell
$105.77

-9.84 (-8.51%)

10/07/16
JPMS
10/07/16
NO CHANGE
JPMS
Overweight
Honeywell selloff on guidance a buying opportunity, says JPMorgan
JPMorgan analyst C. Stephen Tusa recommends using the selloff in shares of Honeywell following the company's Q3 guidance cut as a buying opportunity. The analyst puts himself in the "not that bad in the grand scheme" camp and notes Honeywell has $25B in balance sheet capacity. Tusa has an Overweight rating on the shares.
10/07/16
BERN
10/07/16
NO CHANGE
BERN
Honeywell still has positive attributes, says Bernstein
After Honeywell lowered its guidance and announced restructuring plans, Bernstein analyst Steven Winoker said that macro conditions and margins/restructuring led to the disappointing news. However, the analyst says that there are still multiple reasons to be upbeat on the stock, including his belief that the company's EPS growth will exceed 8% next year, and what he sees as the company's high margins and large cash reserves. The analyst keeps a $135 price target and Outperform rating on the stock.
10/06/16
BARD
10/06/16
INITIATION
Target $135
BARD
Outperform
Honeywell initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Honeywell with an Outperform and a $135 price target.
10/06/16
BARD
10/06/16
INITIATION
Target $135
BARD
Honeywell initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Honeywell with an Outperform and a $135 price target.
GPS Gap
$26.04

3.255 (14.29%)

10/07/16
UBSW
10/07/16
NO CHANGE
Target $16
UBSW
Sell
Gap distribution center fire impact not done being felt, says UBS
UBS analyst Michael Binetti noted Gap's distribution center fire in August had a significant impact on September sales and that the company estimates that the fire will be a 3 point drag to October same-store sales as well. Additionally, Binetti said Florida, Georgia and South Carolina account for 10% of the company's North America store count and that Gap will close some stores amid this weekend's hurricane, further impacting October sales. The company mentioned that merchant margins were higher than expected which should offset any negative earnings impact, however. The analyst is cautious of the company's ability to pull back on promotions to drive a comp inflection and reiterated his Sell rating and $16 price target on Gap shares.
10/07/16
DBAB
10/07/16
UPGRADE
Target $24
DBAB
Hold
Gap upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Paul Trussell upgraded Gap to Hold saying the company's near- to medium-term setup is more favorable amid easing compares over the next few months and an improved apparel backdrop. Trussell raised his price target for the shares to $24 from $18.
10/07/16
10/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Hold from Sell at Deutsche Bank with analyst Paul Trussell saying the company's near-to medium-term setup is more favorable amid easing compares over the next few months and an improved apparel backdrop. 2. DuPont Fabros (DFT) upgraded to Buy from Hold at Stifel with analyst Matthew Heinz saying the company's current valuation reflects an expectation for weaker Q3 leasing activity. 3. Ralph Lauren (RL) upgraded to Conviction Buy from Buy at Goldman with analyst Lindsay Drucker Mann saying CEO Stefan Larsson's turnaround is firmly in place. 4. Restoration Hardware (RH) upgraded to Neutral from Underperform at Buckingham with the firm's analyst believing $1.60-$1.80 fiscal 2016 earnings are achievable, reducing the risk of further downward earnings revisions. 5. Vivint Solar (VSLR) upgraded to Neutral from Sell at Goldman with analyst Brian Lee saying the company is "moving on the path toward recovery." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
JEFF
10/07/16
NO CHANGE
Target $32
JEFF
Buy
Jefferies sees 'sizable upside potential' in Gap shares
Jefferies analyst Randal Konik raises his price target for Gap shares to $32 from $30 following the retailer's September results. Trends are Old Navy are accelerating while a bottom setting in at The Gap, Konik tells investors in a research note. The analyst sees an "asymmetric risk/reward" for shares with downside "fairly limited" and "sizable upside potential." He sees easy comparisons as a near-term catalyst and keeps a Buy rating on the shares.
RL Ralph Lauren
$103.21

1.8 (1.78%)

10/07/16
GSCO
10/07/16
UPGRADE
GSCO
Conviction Buy
Ralph Lauren upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Lindsay Drucker Mann added Ralph Lauren to the Conviction Buy List saying CEO Stefan Larsson's turnaround is firmly in place. Drucker expects a major inventory drawdown over the next 4 quarters, a major push ot upgrade operating capabilities, and cost savings from restructuring activities. The analyst has a $120 price target on Ralph Lauren shares.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Ralph Lauren initiated with a Neutral at Guggenheim
09/28/16
LYON
09/28/16
INITIATION
LYON
Buy
Ralph Lauren initiated with a Buy at CLSA
CLSA analyst Rick Patel initiated Ralph Lauren with a Buy rating and a $125 price target.
ALGT Allegiant Travel
$142.36

2.73 (1.96%)

09/23/16
BUCK
09/23/16
UPGRADE
Target $168
BUCK
Buy
Allegiant Travel upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Allegiant Travel to Buy and increased its price target to $168 from $144. The firm's analyst said Allegiant's move to retire MD80s suggests not only is an operational recovery underway, but that overall earnings growth is underappreciated by the Street. The MD80s have been a source of operational unreliability and year-to-date underperformance provides a buying opportunity, according to the bank.
06/14/16
06/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Achaogen (AKAO) upgraded to Outperform from Neutral at Wedbush with analyst Heather Behanna's physician survey suggesting Achaogen's plazomicin has a niche opportunity that can grow if Phase III data confirms its differentiated safety profile from the aminoglycoside class. 2. Allegiant Travel (ALGT) upgraded to Outperform from Market Perform at Raymond James with analyst Savanthi Syth citing an attractive risk/reward profile. 3. MSA Safety (MSA) upgraded to Buy from Hold at Stifel with the firm saying that demand for the company's self-contained breathing apparatus has been stronger than expected. 4. Penn West Petroleum (PWT) upgraded to Hold from Sell at Desjardins and to Sector Perform from Underperform at Scotiabank with Scotiabank analyst Jamie Kubik saying financing and non-core asset sales have freed up liquidity. 5. Vonage (VG) upgraded to Buy from Neutral at Citi with analyst Michael Rollins citing a favorable risk/reward scenario given the company's opportunity to improve business revenue growth and generate a free cash flow yield at over 10%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
IMPC
10/07/16
INITIATION
Target $164
IMPC
Outperform
Allegiant Travel initiated with an Outperform at Imperial Capital
Imperial Capital analyst Michael Derchin started Allegiant Travel with an Outperform rating and $164 price target. The company's "differentiated, low cost business model with strong growth prospects" is not fully reflected in current equity values, Derchin tells investors in a research note.
08/30/16
RAJA
08/30/16
UPGRADE
RAJA
Outperform
United Continental upgraded to Outperform from Market Perform at Raymond James
As previously reported, Raymond James analyst Savanthi Syth upgraded United Continental to Outperform with a $65 price target following the announcement of Scott Kirby as President and Andrew Levy as CFO. Kirby joins United from American Airlines (AAL), as announced last night, and Levy joins from Allegiant Travel (ALGT), as announced earlier this month. The analyst said both executives have strong industry experience and Syth has increased conviction United will reduce it margin gap relative to its peers over the next 12-18 months. Further, competitive capacity pressures will likely improve and easing comps should benefit sequential revenue trends in 2017, the analyst tells investors.
CLVS Clovis
$35.77

-1.51 (-4.05%)

10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
10/07/16
RHCO
10/07/16
NO CHANGE
Target $50
RHCO
Buy
Clovis selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson views today's selloff in shares of Clovis Oncology as a buying opportunity, saying today's concern "seems like noise." The analyst has a Buy rating on the stock with a $50 price target. Clovis is down 13%, or $4.64, to $31.13 but is well off the day's lows.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
AZN AstraZeneca
$32.05

-0.21 (-0.65%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
PPG PPG
$93.17

-9.02 (-8.83%)

05/06/16
LYON
05/06/16
DOWNGRADE
LYON
Outperform
PPG Industries downgraded to Outperform from Buy at CLSA
10/07/16
WELS
10/07/16
NO CHANGE
WELS
PPG Industries removed from Priority List at Wells Fargo
07/26/16
GHSC
07/26/16
UPGRADE
Target $130
GHSC
Buy
PPG Industries upgraded to Buy from Accumulate at Seaport Global
Seaport Global analyst Michael Harrison upgraded PPG to Buy from Accumulate and raised its price target to $130 from $125. The analyst increased the outlook for the coatings business and adjusted the model to reflect the divestiture of most the Glass segment and said PPG is a high-quality core holding that should be able to leverage organic and inorganic growth opportunities, maintain focus on cost discipline, and return cash to shareholders.
06/23/16
LBOW
06/23/16
UPGRADE
LBOW
Buy
PPG Industries upgraded to Buy from Neutral at Longbow
Longbow analyst Dmitry Silverstein upgraded PPG Industries to Buy with a $130 price target on shares. The analyst believes PPG's efforts to improve organic growth may be gaining momentum given evidence of accelerating growth in PPG's store channel and increased traction from new higher priced products at Menards. Further, faster growth of auto-OEM, Industrial, Aerospace and EMEA businesses in 2H16, driving above-consensus performance, upward earnings revisions and expanding multiples, the analyst wrote.
TSN Tyson Foods
$66.58

-7.8 (-10.49%)

10/07/16
10/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) downgraded to Sell from Hold at Pivotal Research with analyst Timothy Ramey citing the broiler price-fixing alleged in the class action complaint filed on September 2. 2. SolarEdge (SEDG) was downgraded to Sell from Neutral at Goldman while the firm also downgraded First Solar (FSLR) to Neutral from Buy. 3. CIT Group (CIT) downgraded to Hold from Buy at Stifel with analyst Christopher Brendler saying investors should sell into the rally that will result from the "impressive" price that the company received for its aircraft business and the approval of its capital plan by the Fed. 4. Fifth Third (FITB) downgraded to Hold from Buy at Jefferies with analyst Ken Usdin saying the shares are reasonably valued following the recent rally. 5. Blackhawk (HAWK) downgraded to Neutral from Buy at BofA/Merrill with analyst David Chu saying the firm's channel checks indicate that conversions to EMV, the new standard for chip-based debit/credit card transactions, are taking longer than expected, which he believes could impact Blackhawk's 2016 guidance and expectations for 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
PIVT
10/07/16
DOWNGRADE
PIVT
Sell
Tyson Foods downgraded to Sell from Hold at Pivotal Research
Pivotal analyst Timothy Ramey downgraded Tyson Foods to Sell and slashed his price target to $40 from $100 due to the broiler price-fixing alleged in the class action complaint filed on September 2. Ramey said the complain alleges supply collusion occurred through nonpublic data exchange; detailed industry reports compiled on a daily or weekly basis by Agri Stats. Supposedly, the data has telling clues as to the identity of the other industry participants, making it is easy for the industry to collude on production cuts since they provide non-public information to Agri Stats on future production intentions. The analyst wondered why margins improved dramatically over the past seven years in a historically undisciplined industry. Ramey believes the class-action suit has merit and will lead to intense scrutiny of the broiler industry and questions the sustainability of chicken margins. He expects Tyson shares will be pressured until this complex issue is resolved and damages could be very substantial.
07/26/16
CLVD
07/26/16
NO CHANGE
CLVD
Buy
Tyson Foods estimates raised further above consensus at Cleveland Research
Cleveland Research analyst Mike Piken raised Tyson Foods' FY16 and FY17 estimates further above consensus on improved chicken and beef outlook. The analyst is modeling Q3 earnings of $1.11, versus consensus of $1.05, driven by expectations for stronger beef EBIT margins, raised Q4 to $1.08, versus consensus of $1.06, to reflect a strong start for Pork, revised FY16 to $4.40, above consensus of $4.33, and FY17 to $4.79, versus consensus of $4.60. Piken rates Tyson a Buy.
09/19/16
SPHN
09/19/16
NO CHANGE
Target $85
SPHN
Overweight
Stephens makes Tyson Foods new Best Idea in Food and Agribusiness
Stephens analyst Farha Aslam is making Tyson Foods her firm's new Best Idea in Food and Agribusiness as she believes the company is well positioned for long-term growth. Consumers' growing interest in protein rich foods is creating opportunities to innovate new products, create brands in previously commodity categories, and improve margins, she added. Aslam reiterates an Overweight rating and $85 price target on the shares.

TODAY'S FREE FLY STORIES

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

16:57
09/22/17
09/22
16:57
09/22/17
16:57
Hot Stocks
Allergan receives refusal to file letter from FDA for Vraylar »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

HON

Honeywell

$141.75

0.89 (0.63%)

, CC

Chemours

$51.79

-0.16 (-0.31%)

16:51
09/22/17
09/22
16:51
09/22/17
16:51
Hot Stocks
Honeywell, Chemours seek rehearing of D.C Court decision regarding SNAP program »

Honeywell (HON) and…

HON

Honeywell

$141.75

0.89 (0.63%)

CC

Chemours

$51.79

-0.16 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOE

Saint Joe Co.

$18.60

0.45 (2.48%)

16:46
09/22/17
09/22
16:46
09/22/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Saint Joe Co. »

Fairholme raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TYHT

Shineco

$3.23

-0.45 (-12.23%)

16:35
09/22/17
09/22
16:35
09/22/17
16:35
Hot Stocks
Shineco enters into strategic cooperation to establish Apocynum Industrial Park »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:34
09/22/17
09/22
16:34
09/22/17
16:34
Hot Stocks
Appliance Recycling gets written notice of default »

On September 20,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Rennova Health announces 1 for 15 reverse stock split »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Breaking Hot Stocks news story on Appliance Recycling »

Appliance Recycling gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/22/17
09/22
16:30
09/22/17
16:30
Options
Preliminary option volume of 13.9M today »

Preliminary option volume…

EKSO

Ekso Bionics

$1.28

0.14 (12.28%)

16:23
09/22/17
09/22
16:23
09/22/17
16:23
Hot Stocks
Ekso Bionics awarded government contract »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

, AET

Aetna

$153.57

0.18 (0.12%)

16:22
09/22/17
09/22
16:22
09/22/17
16:22
General news
On The Fly: Top stock stories for Friday »

The major averages…

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CI

Cigna

$182.74

0.61 (0.33%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

FSLR

First Solar

$51.41

2.65 (5.43%)

FINL

Finish Line

$9.73

0.51 (5.53%)

ASND

Ascendis Pharma

$34.24

6.5 (23.43%)

VSAR

Versartis

$2.68

-18.925 (-87.62%)

ICPT

Intercept

$61.59

-12.11 (-16.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DLR

Digital Realty

$114.51

-1.72 (-1.48%)

16:19
09/22/17
09/22
16:19
09/22/17
16:19
Syndicate
Breaking Syndicate news story on Digital Realty »

Digital Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.